FDA Approves Trial for Next-Gen Transcatheter Valve
September 23, 2010 – The U.S. Food and Drug Administration (FDA) has conditionally approved the first part of a trial testing a new transcatheter heart valve.
The first cohort of the Partner II trial will study the Edwards Sapien XT transcatheter heart valve and the low-profile NovaFlex transfemoral delivery system. Partner II will study up to 450 patients with severe, symptomatic aortic stenosis using two-to-one randomization, where for every two patients who receive the valve delivered transfemorally, one will receive standard therapy.
A second patient cohort will compare traditional open-heart surgery with the Sapien XT delivered either transfemorally or transapically.
The transcatheter valve received a CE mark in March 2010, but is not yet commercially available in the United States.
For more information: www.edwards.com
More like this
- New Transcatheter Valve and Delivery Systems Receive CE Mark
- Edwards Announces First Human Implants With 18 French Transcatheter Valve
- European Registry of 2,300 Transcatheter Valve Patients Shows Good One-Year Outcomes
- Sapien XT Transcatheter Valve Continues to Achieve Positive Outcomes
- CE Mark Approves Transcatheter Heart Valve